Latest Daily News

More Stories

July 23, 2018

The 2018 ASCO Annual Meeting featured the results of multiple large phase III trials aimed at establishing whether the use of PD-1/PD-L1 checkpoint inhibitors can enhance outcomes in metastatic non–small cell lung cancer (NSCLC).

Read more

July 23, 2018

Lung cancer is a notoriously difficult condition to treat, with mortality rates exceeding those from the next four deadliest cancers—breast, colon, prostate, and pancreatic—combined.

Read more

June 14, 2018

Amidst the flood of immunotherapy trials being conducted in non–small cell lung cancer (NSCLC), interim data from two pivotal phase III trials of atezolizumab are beginning to inform if and how the anti–PD-L1 inhibitor may be used in the first-line setting.

Read more

June 14, 2018

Adding bevacizumab to the tyrosine kinase inhibitor (TKI) erlotinib significantly extended progression free-survival (PFS) in patients with late-stage or recurrent chemotherapy-naive EGFR-mutated non–small cell lung cancer (NSCLC) with good tolerability.

Read more

June 14, 2018

Dacomitinib is a second-generation EGFR tyrosine kinase inhibitor (TKI). This agent was compared with gefitinib in the phase III open-label ARCHER1050 trial in patients with advanced non–small cell lung cancer (NSCLC) with EGFR-activating mutations.

Read more

June 4, 2018

Pembrolizumab significantly improved overall survival (OS) compared with platinum-based chemotherapy as first-line therapy for patients with advanced/metastatic non–small cell lung cancer (NSCLC).

Read more

June 4, 2018

Comprehensive sequencing of plasma cell-free DNA (cfDNA) demonstrates the ability to noninvasively detect lung cancer with reliable specificity and sensitivity.

Read more

June 4, 2018

Pembrolizumab significantly improved overall survival (OS) compared with platinum-based chemotherapy as first-line therapy for patients with advanced/metastatic non–small cell lung cancer (NSCLC).

Read more

June 3, 2018

Combining pembrolizumab with conventional chemotherapy in the first-line setting significantly prolongs median overall survival (OS) in patients with metastatic squamous non–small cell lung cancer (NSCLC)

Read more

May 16, 2018

ASCO recently released a new Clinical Practice Guideline on the management of malignant pleural mesothelioma.

Read more

May 14, 2018

When we were asked to write an Expert Editorial about smoking cessation in patients with cancer, our first thought was, isn’t this topic settled and already well understood?

Read more

May 14, 2018

By 2030, the number of deaths due to lung cancer is expected to almost double for Latin American women and increase by 50% for Latin American men.

Read more

May 14, 2018

The therapeutic landscape of advanced non–small cell lung cancer (NSCLC) has seen a rapid shift in the last 2 years with the introduction of immunotherapy into treatment algorithms.

Read more

May 11, 2018

Nagashree Seetharamu, MD, MBBS, answers a question posed by an attendee at a Best of ASCO® Meeting.

Read more

June 6, 2017

Researchers presented results of four studies evaluating new approaches to targeted therapies for patients with lung cancer, including metastatic non–small cell lung cancer.

Read more
June 5, 2017

Both nivolumab alone and in combination with ipilimumab resulted in a promising disease control rate in patients with relapsing malignant pleural mesothelioma (MPM), according to the results of Abstract LBA8507.

Read more
June 5, 2017

The EGFR tyrosine-kinase inhibitor gefitinib appears to offer a disease-free survival benefit over vinorelbine/cisplatin as adjuvant therapy in patients with non–small cell lung cancer with EGFR-activating mutation.

Read more

June 3, 2017

Presenters discussed current concepts regarding the treatment of early-stage disease, along with efforts to better enhance local control.

Read more
June 2, 2017

Researchers overseeing the trial at Roswell Park discuss the effectiveness of CIMAvax-EGF in NSCLC, the results of completed clinical trials in Cuba, and the long-term plans for additional testing of the vaccine.

Read more
May 25, 2017

Smoking not only causes many forms of cancer, but continued smoking by people with cancer and cancer survivors causes adverse health outcomes, including increased overall mortality, cancer-specific mortality, and risk for second primary cancer and is associated with increased treatment toxicity.

Read more